Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Takeda K, Yamamoto M. Aruga A, et al. Among authors: okuyama r. Clin Cancer Res. 2013 Apr 15;19(8):2224-31. doi: 10.1158/1078-0432.CCR-12-3592. Epub 2013 Mar 11. Clin Cancer Res. 2013. PMID: 23479678 Clinical Trial.
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.
Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, Takechi T, Yamamoto M, Hayashi K. Nakamura A, et al. Among authors: okuyama r. Gastric Cancer. 2014 Jan;17(1):188-95. doi: 10.1007/s10120-013-0249-7. Epub 2013 Mar 15. Gastric Cancer. 2014. PMID: 23494117 Free PMC article.
Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.
Nakamura A, Hayashi K, Nakajima G, Kamikozuru H, Okuyama R, Kuramochi H, Hatori T, Yamamoto M. Nakamura A, et al. Among authors: okuyama r. Exp Ther Med. 2011 Nov;2(6):1097-1103. doi: 10.3892/etm.2011.340. Epub 2011 Aug 22. Exp Ther Med. 2011. PMID: 22977627 Free PMC article.
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H, Ando M, Itabashi M, Nakajima G, Kawakami K, Hamano M, Hirai E, Yokomizo H, Okuyama R, Araida T, Yoshimatsu K, Kameoka S, Hayashi K. Kuramochi H, et al. Among authors: okuyama r. Cancer Chemother Pharmacol. 2017 Mar;79(3):579-585. doi: 10.1007/s00280-017-3255-3. Epub 2017 Feb 17. Cancer Chemother Pharmacol. 2017. PMID: 28213683 Clinical Trial.
353 results